Can a new pill shrink the spleen in myelofibrosis?

NCT ID NCT06457425

Ongoing Disease control Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial is testing an experimental drug called flonoltinib in people with intermediate to high-risk myelofibrosis, a type of bone marrow cancer that often causes an enlarged spleen. Participants will be randomly assigned to receive either a low or high dose of flonoltinib, or the standard drug ruxolitinib. The main goal is to see if flonoltinib can reduce spleen size by at least 35%, which would indicate it may be a useful treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: flonoltinib maleate tablets
What this could lead to: If successful, flonoltinib could offer a new treatment option for myelofibrosis, potentially reducing spleen size and improving symptoms.
What could go wrong: This is an early-phase trial with a small number of participants. It may not show a clear benefit over the existing drug ruxolitinib, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MF,PMF,PPV-MF,PET-MF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MF,PMF,PPV-MF,PET-MF

Contacts and locations

Locations

Hematology Hospital, Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, 300052, China
West China Hospital Sichuan University

Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.